BioNixus intelligence for Business Growth
Strategic portfolio

Market research & strategic consulting portfolio

Actionable intelligence across healthcare and consumer sectors — trusted by leading pharmaceutical organizations and ambitious enterprises in Egypt and the broader MENA region.

127
Projects
48
Global clients
18
Countries
15
Years track record
BioNixus Market Research & Consulting April 2026 Healthcare · Consumer · MENA
01
Portfolio snapshot

Scope of engagements

Over a 15-year track record, BioNixus has completed 50–120 projects annually spanning primary research, competitive intelligence, market access strategy, and consumer insights across multiple geographies.

84

Healthcare & pharma

Market sizing, pricing & reimbursement, HTA dossiers, KOL mapping, competitive landscape, launch readiness.

43

Consumer & corporate

Brand health, satisfaction, market entry feasibility, digital transformation, strategic due diligence.

32

MENA-focused studies

GCC, Egypt, North Africa — Arabic qualitative capability and local regulatory knowledge.

15

Multi-country programs

Coordinated research across Europe, MENA, Asia-Pacific, and the Americas for global HQs.

Project mix by stream

Share of tracked engagements (illustrative composition).

Healthcare & pharma
48%
Consumer & corporate
25%
MENA-focused
18%
Multi-country
9%

Sector concentration

Life sciences vs. corporate & consumer portfolio.

Life sciences & pharma — 66%
Corporate & consumer — 34%

Indexed trend of mandate volume — representative trajectory for reporting purposes.

02
Capabilities

Research & consulting depth

Therapeutic-area expertise, rigorous methods, and local-market intelligence — structured for decisions that move P&L, access, and customer experience.

Healthcare & life sciences

Market access & pricingReimbursement landscaping, HTA submissions, value dossiers
Competitive intelligencePipeline analytics, benchmarking, patent cliff analysis
Primary market researchKOL interviews, patient journey mapping, ATU studies
Launch excellencePre-launch assessment, demand forecasting, GTM planning
Pharmacoeconomics & HEORCE models, budget impact, RWE studies
Regulatory & policyGCC pathways, SFDA / EDA / DHA frameworks

Consumer & corporate

Market entry & feasibilityOpportunity sizing, competitive mapping, risk assessment
Customer experienceNPS programs, satisfaction tracking, journey optimization
Brand strategyEquity measurement, repositioning roadmaps
Digital transformationTechnology assessment, process redesign, change management
Strategic due diligenceM&A support, commercial assessment, synergies
Workforce & operationsProductivity studies, operational benchmarking
From raw signals to board-ready synthesis — triangulation across primary, secondary, and proprietary sources.
03
Client footprint

Global pharma relationships

Delivered as principal contractor or specialist subcontractor for leading pharmaceutical and biotech organizations.

17
Top-20 global pharma
10
Specialty & biotech
6
MENA leaders
Relationship depth index by client tier Three horizontal bars compare indexed engagement depth for top-twenty global pharma, specialty and biotech, and MENA regional leaders, against a 0 to 100 percent scale. Relationship depth index, by tier Share of maximum observed depth (indexed to top tier = 100) 0 25 50 75 100 Top 20 — global pharma 51% Specialty & biotech 30% MENA leaders 18% Depth index (% of benchmark)

Benchmark reflects composite of mandate complexity, repeat engagements, and cross-border coordination — normalized so the deepest tier (top 20 global) maps to 100.

Big pharma — top 20 global
Pfizer
Roche
Novartis
Johnson & Johnson
Merck & Co. (MSD)
AstraZeneca
Sanofi
AbbVie
GSK
Eli Lilly
Bristol-Myers Squibb
Amgen
Gilead Sciences
Novo Nordisk
Bayer
Takeda
Boehringer Ingelheim
Specialty pharma & biotech
Biogen
Regeneron
Astellas
Daiichi Sankyo
Ipsen
Servier
LEO Pharma
Lundbeck
UCB
Organon
MENA & emerging market leaders
Hikma Pharmaceuticals
Julphar
SPIMACO
Tabuk Pharmaceuticals
EIPICO
Tamer Group
04
Egypt case studies

Impact, locally delivered

Selected engagements across financial services, tourism & transport, manufacturing, mobility, and diagnostics.

Egypt case portfolio — sector mix Portfolio mix by sector: diagnostics and healthcare 30 percent, financial services 20, tourism and transport 14, industrial manufacturing 25, mobility and technology 11. Portfolio mix by sector 0% 33% 67% 100% Diagnostics & healthcare 30% Financial services 20% Tourism & transport 14% Industrial manufacturing 25% Mobility & technology 11%
CIB
Financial services

Workplace research and strategy program

BioNixus designed and executed a multi-phase research program for the Commercial International Bank to benchmark COVID-affected employees and how to take measures in diagnosis, treatment, working from home, safe return zones, and restructure across retail and SME segments, evaluate new strategy adoption, and inform the bank's crisis management roadmap. The engagement combined quantitative surveys of 3,000+ employees with qualitative tracking of medical and productivity status.

3,000+
Employees surveyed
4 Phases
Research waves
12 Weeks
Delivery · 1-yr contract
Traveco and TEZ Tours
Tourism & transport

Market expansion & competitive positioning

Engaged by Traveco and TEZ Tours to conduct an end-to-end market feasibility study for expanding tourism services into underserved governorates. BioNixus delivered operational model optimization and a 1-year strategic roadmap with phased regional rollout recommendations.

3
Governorates mapped
1-Year
Strategic roadmap
28%
Projected revenue uplift
Coats Egypt
Industrial manufacturing

Operational benchmarking & workforce optimization

BioNixus partnered with Coats Egypt — the local arm of Coats Group plc — to conduct a comprehensive operational benchmarking study comparing plant productivity, workforce utilization, and benefits against peers.

22%
Efficiency gain identified
3 Plants
Benchmarked
Lean + Digital
Transformation plan
SWVL & Hail — Riding & Transport Startup
Mobility & technology

Growth strategy research

Conducted an in-depth segmentation and willingness-to-pay study for Egypt operations. Deliverables included a dynamic pricing sensitivity model and targeted acquisition strategy that informed a B2B corporate shuttle pivot and UAE expansion.

5
Segments defined
Pricing model
Dynamic WTP engine
B2B pivot
Strategic input
Cairo Labs
Diagnostics & healthcare

Service portfolio optimization & patient journey

BioNixus conducted a comprehensive review of Cairo Labs' diagnostic service portfolio, mapping the full patient referral journey from physician ordering to result delivery. The engagement identified bottlenecks in turnaround time, proposed a tiered service model, and delivered a digital pre-analytics workflow design to reduce sample rejection rates.

40%
TAT improvement target
Tiered model
Service redesign
Digital workflow
Pre-analytics blueprint
Hassab Diagnostics
Diagnostics & healthcare

Brand positioning & market entry — specialized testing

Supported Hassab Diagnostics in developing a go-to-market strategy for their expanded diagnostics and specialty testing capabilities and Cairo expansion. BioNixus delivered competitor positioning analysis, referral network mapping, Cairo site selection analysis, and a pricing architecture aligned to both private-pay and co-pay reimbursement channels.

Diagnostics Dx
Launch strategy
200+
Clients · referral map
Dual pricing
Private + co-pay
05
Operating model

Research-to-action methodology

Structured yet adaptive — designed to translate evidence into commercial outcomes and implementation discipline.

01

Scope & design

Collaborative briefing, hypothesis formulation, and bespoke research design tailored to the decision at hand.

02

Intelligence gathering

Multi-modal data collection — primary interviews, secondary desk research, proprietary databases, and field audits.

03

Analysis & synthesis

Rigorous triangulation, advanced analytics, and expert validation to surface patterns and strategic implications.

04

Strategic delivery

Boardroom-ready outputs with clear recommendations, implementation roadmaps, and ongoing advisory support.

Plan your next healthcare or consumer mandate

Share your objectives for physician research, access strategy, or corporate insight programs — the BioNixus team will respond with a scoped approach aligned to your timeline and markets.

Request a consultation admin@bionixus.com